The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cerazette     (8S,9S,10R,13S,14S,17S)-13- ethyl-17...

Synonyms: Cyclessa, DESOGESTREL, Org-2969, Org2969, ORG 2969, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of DESOGESTREL

  • BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens [1].
  • This phenomenon, designated as acquired APC resistance, is more pronounced in women using desogestrel-containing oral contraceptives than in women using levonorgestrel-containing preparations [2].
  • It has been suggested that preparations containing the newer progestogens, Desogestrel and Gestodene, are not associated with any increase in risk of myocardial infarction, but there is not yet sufficient evidence to test this hypothesis [3].
  • Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives [4].
  • The risk of development of deep vein thrombosis was also found to be 2 to 5 times greater with a low-estrogen, desogestrel-containing oral contraceptive than with second-generation monophasic and triphasic preparations [5].

High impact information on DESOGESTREL


Chemical compound and disease context of DESOGESTREL

  • CONCLUSION(S): Oral contraceptive pills containing low-dose ethinyl estradiol and desogestrel are effective in controlling hyperandrogenism and hirsutism and ameliorate the abnormal metabolic profile of women with hirsutism [10].
  • Recent data indicate that users of third-generation oral contraceptives, those containing the new progestins desogestrel, gestodene, and norgestimate, have 2 to 3 times the risk of venous thromboembolism faced by users of second-generation oral contraceptives [5].
  • Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men [11].
  • AIMS: In October 1995 in response to the results of three studies, the Committee on the Safety of Medicines advised doctors and pharmacists that oral contraceptives containing desogestrel (DSG) and gestodene (GST) were associated with around a two-fold increase in the risk of thromboembolism compared with those containing other progestogens [12].
  • The desogestrel-containing preparations Gracial and Marvelon, and possibly also the gestodene-containing preparation Gynera, have demonstrated a good efficacy in well-controlled studies in the treatment of mild to moderate acne and/or hirsutism [13].

Biological context of DESOGESTREL


Anatomical context of DESOGESTREL


Associations of DESOGESTREL with other chemical compounds


Gene context of DESOGESTREL


Analytical, diagnostic and therapeutic context of DESOGESTREL

  • One group was taking an oral contraceptive (150 microg desogestrel and 30 microg ethinyl estradiol); the other group (control) was not [29].
  • We conclude that daily self-administered desogestrel with transdermal T is capable of suppressing the male reproductive axis, although the efficacy was less marked and less consistent than injectable regimens [30].
  • We measured serum FSH and LH using a modified, highly sensitive immunofluorometric assay in samples obtained from three published studies using T enanthate (TE; 100 and 200 mg weekly) plus daily oral doses of cyproterone acetate (CPA; 5-100 mg), levonogestrel (LNG; 150-500 micro g), or desogestrel (DSG; 150-300 micro g) [31].
  • Four epidemiologic studies showed a two-fold increase in risk of VTE with the use of OCs containing third-generation progestins (gestodene and desogestrel), relative to second-generations products (levonorgestrel) [32].
  • A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways [25].


  1. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Farmer, R.D., Lawrenson, R.A., Thompson, C.R., Kennedy, J.G., Hambleton, I.R. Lancet (1997) [Pubmed]
  2. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Rosing, J., Middeldorp, S., Curvers, J., Christella, M., Thomassen, L.G., Nicolaes, G.A., Meijers, J.C., Bouma, B.N., Büller, H.R., Prins, M.H., Tans, G. Lancet (1999) [Pubmed]
  3. Oral contraceptives and myocardial infarction: new evidence leaves unanswered questions. Thorogood, M. Thromb. Haemost. (1997) [Pubmed]
  4. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Porcile, A., Gallardo, E. Fertil. Steril. (1991) [Pubmed]
  5. Risk of venous thromboembolism with third-generation oral contraceptives: A review. Weiss, G. Am. J. Obstet. Gynecol. (1999) [Pubmed]
  6. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Poulter, N.R., Chang, C.L., Farley, T.M., Marmot, M.G., Meirik, O. Lancet (1999) [Pubmed]
  7. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Kemmeren, J.M., Algra, A., Meijers, J.C., Tans, G., Bouma, B.N., Curvers, J., Rosing, J., Grobbee, D.E. Blood (2004) [Pubmed]
  8. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives. Haarbo, J., Hassager, C., Jensen, S.B., Riis, B.J., Christiansen, C. Am. J. Med. (1991) [Pubmed]
  9. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. Cagnacci, A., Paoletti, A.M., Renzi, A., Orrù, M., Pilloni, M., Melis, G.B., Volpe, A. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  10. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Escobar-Morreale, H.F., Lasunción, M.A., Sancho, J. Fertil. Steril. (2000) [Pubmed]
  11. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Kinniburgh, D., Zhu, H., Cheng, L., Kicman, A.T., Baird, D.T., Anderson, R.A. Hum. Reprod. (2002) [Pubmed]
  12. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Farmer, R.D., Lawrenson, R.A., Todd, J.C., Williams, T.J., MacRae, K.D., Tyrer, F., Leydon, G.M. British journal of clinical pharmacology. (2000) [Pubmed]
  13. Classification and comparison of oral contraceptives containing new generation progestogens. Newton, J.R. Hum. Reprod. Update (1995) [Pubmed]
  14. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. Wu, F.C., Balasubramanian, R., Mulders, T.M., Coelingh-Bennink, H.J. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  15. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Meijers, J.C., Middeldorp, S., Tekelenburg, W., van den Ende, A.E., Tans, G., Prins, M.H., Rosing, J., Büller, H.R., Bouma, B.N. Thromb. Haemost. (2000) [Pubmed]
  16. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Kemmeren, J.M., Algra, A., Meijers, J.C., Bouma, B.N., Grobbee, D.E. Thromb. Haemost. (2002) [Pubmed]
  17. Bone mineral density in young women with long-standing amenorrhea: limited effect of hormone replacement therapy with ethinylestradiol and desogestrel. Haenggi, W., Casez, J.P., Birkhaeuser, M.H., Lippuner, K., Jaeger, P. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1994) [Pubmed]
  18. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives. Norris, L.A., Bonnar, J. Thromb. Haemost. (1994) [Pubmed]
  19. Comparative pharmacology of newer progestogens. Kuhl, H. Drugs (1996) [Pubmed]
  20. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. Gentile, D.M., Verhoeven, C.H., Shimada, T., Back, D.J. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  21. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Madden, S., Back, D.J., Martin, C.A., Orme, M.L. British journal of clinical pharmacology. (1989) [Pubmed]
  22. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Jick, H., Jick, S.S., Gurewich, V., Myers, M.W., Vasilakis, C. Lancet (1995) [Pubmed]
  23. Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting. Hedenmalm, K., Samuelsson, E. Drug safety : an international journal of medical toxicology and drug experience. (2005) [Pubmed]
  24. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Speroff, L., DeCherney, A. Obstetrics and gynecology. (1993) [Pubmed]
  25. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Tans, G., Curvers, J., Middeldorp, S., Thomassen, M.C., Meijers, J.C., Prins, M.H., Bouma, B.N., Büller, H.R., Rosing, J. Thromb. Haemost. (2000) [Pubmed]
  26. Marked gender differences in ambulatory morning growth hormone values in young adults. Engström, B.E., Karlsson, F.A., Wide, L. Clin. Chem. (1998) [Pubmed]
  27. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Brady, B.M., Anderson, R.A., Kinniburgh, D., Baird, D.T. Clin. Endocrinol. (Oxf) (2003) [Pubmed]
  28. Advantage of desogestrel containing pill in oral contraception: influence on blood lipids and LCAT activity. Pansini, F., Ferrari, C., Guerra, S., Bassi, P., Guzzinati, N., Cocilovo, G., Mollica, G. Clinical and experimental obstetrics & gynecology. (1987) [Pubmed]
  29. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. Seidegård, J., Simonsson, M., Edsbäcker, S. Clin. Pharmacol. Ther. (2000) [Pubmed]
  30. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. Hair, W.M., Kitteridge, K., O'Connor, D.B., Wu, F.C. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  31. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. McLachlan, R.I., Robertson, D.M., Pruysers, E., Ugoni, A., Matsumoto, A.M., Anawalt, B.D., Bremner, W.J., Meriggiola, C. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  32. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Helmerhorst, F.M., Bloemenkamp, K.W., Rosendaal, F.R., Vandenbroucke, J.P. Thromb. Haemost. (1997) [Pubmed]
WikiGenes - Universities